Forma Therapeutics Statistics
Share Statistics
Forma Therapeutics has 0
shares outstanding. The number of shares has increased by -4.38%
in one year.
| Shares Outstanding | n/a |
| Shares Change (YoY) | -4.38% |
| Shares Change (QoQ) | -4.44% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -3.38 and the forward
PE ratio is null.
Forma Therapeutics's PEG ratio is
-0.09.
| PE Ratio | -3.38 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 1.17 |
| P/FCF Ratio | -3.79 |
| PEG Ratio | -0.09 |
Financial Ratio HistoryEnterprise Valuation
Forma Therapeutics has an Enterprise Value (EV) of 539.6M.
| EV / Sales | 0 |
| EV / EBITDA | -3.15 |
| EV / EBIT | -3.6 |
| EV / FCF | -3.5 |
Financial Position
The company has a current ratio of 13.86,
with a Debt / Equity ratio of 0.07.
| Current Ratio | 13.86 |
| Quick Ratio | 13.86 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | -0.19 |
| Debt / FCF | -0.21 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is -34.71% and Return on Invested Capital is -32.57%.
| Return on Equity | -34.71% |
| Return on Assets | -30.83% |
| Return on Invested Capital | -32.57% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-915,153.44 |
| Employee Count | 189 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 154K |
| Effective Tax Rate | -0.09% |
Stock Price Statistics
The stock price has increased by 0% in the
last 52 weeks. The beta is -0.95, so Forma Therapeutics's
price volatility has been lower than the market average.
| Beta | -0.95 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 16.65 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 86.85 |
| Average Volume (20 Days) | 1,553,402 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -172.81M |
| Net Income | -172.96M |
| EBITDA | -171.24M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.21 |
Full Income StatementBalance Sheet
The company has 77.42M in cash and 32.74M in
debt, giving a net cash position of 44.68M.
| Cash & Cash Equivalents | 77.42M |
| Total Debt | 32.74M |
| Net Cash | 44.68M |
| Retained Earnings | -230.37M |
| Total Assets | n/a |
| Working Capital | n/a |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -149.79M
and capital expenditures -4.18M, giving a free cash flow of -153.97M.
| Operating Cash Flow | -149.79M |
| Capital Expenditures | -4.18M |
| Free Cash Flow | -153.97M |
| FCF Per Share | -3.75 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
